Nektar Therapeutics (NKTR) EBIAT (2016 - 2025)
Historic EBIAT for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.5 million.
- Nektar Therapeutics' EBIAT rose 414.23% to -$35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.7 million, marking a year-over-year increase of 2826.19%. This contributed to the annual value of -$119.0 million for FY2024, which is 5690.69% up from last year.
- Latest data reveals that Nektar Therapeutics reported EBIAT of -$35.5 million as of Q3 2025, which was up 414.23% from -$41.6 million recorded in Q2 2025.
- Over the past 5 years, Nektar Therapeutics' EBIAT peaked at $7.3 million during Q4 2024, and registered a low of -$159.1 million during Q2 2022.
- In the last 5 years, Nektar Therapeutics' EBIAT had a median value of -$52.4 million in 2024 and averaged -$74.5 million.
- Per our database at Business Quant, Nektar Therapeutics' EBIAT crashed by 5689.88% in 2021 and then soared by 11725.56% in 2024.
- Quarter analysis of 5 years shows Nektar Therapeutics' EBIAT stood at -$145.6 million in 2021, then skyrocketed by 59.02% to -$59.7 million in 2022, then grew by 29.5% to -$42.1 million in 2023, then soared by 117.26% to $7.3 million in 2024, then crashed by 589.22% to -$35.5 million in 2025.
- Its last three reported values are -$35.5 million in Q3 2025, -$41.6 million for Q2 2025, and -$50.9 million during Q1 2025.